Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 249.91 on Tuesday. Puma Biotechnology has a 1-year low of $33.70 and a 1-year high of $263.34. The stock’s 50-day moving average is $166.2 and its 200-day moving average is $108.3. The company’s market cap is $7.527 billion.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.93 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a buy rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an outperform rating on the stock.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.